Abstract:Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the accumulation of malignant plasma cells. The pathogenesis of MM involves the interaction between MM cells and the bone marrow microenvironment through soluble cytokines and cell adhesion molecules, which activate various signaling pathways such as PI3K/AKT/mTOR, RAS/MAPK, JAK/STAT, Wnt/β-catenin, and NF-κB pathways. Aberrant activation of these pathways contributes to the proliferation, survival, migration, and drug resistance of myeloma cells, making them attractive targets for therapeutic intervention. Currently, approved drugs targeting these signaling pathways in MM are limited, with many inhibitors and inducers still in preclinical or clinical research stages. Therapeutic options for MM include non-targeted drugs like alkylating agents, corticosteroids, immunomodulatory drugs, proteasome inhibitors, and histone deacetylase inhibitors. Additionally, targeted drugs such as monoclonal antibodies, chimeric antigen receptor T cells, bispecific T-cell engagers, and bispecific antibodies are being used in MM treatment. Despite significant advancements in MM treatment, the disease remains incurable, emphasizing the need for the development of novel or combined targeted therapies based on emerging theoretical knowledge, technologies, and platforms. In this review, we highlight the key role of signaling pathways in the malignant progression and treatment of MM, exploring advances in targeted therapy and potential treatments to offer further insights for improving MM management and outcomes.

Treatment of multiple myeloma-related bone disease

[A Multi-Centers Clinical Study of Different Treatment Outcomes of 332 Patients with Multiple Myeloma].

Advances in the pathogenesis of multiple myeloma bone disease

Immunotherapy Strategies Against Multiple Myeloma

[Research Advances on Treatment of Multiple Myeloma Bone Disease--Review].

Emerging treatment approaches for myeloma-related bone disease

Treatment strategies for bone disease

Multiple myeloma in the marrow: pathogenesis and treatments

Multiple Myeloma and Bone: The Fatal Interaction

[Surgery for Multiple Myeloma of the Bone].

Therapeutic targets in myeloma bone disease

Receptor Activator of Nuclear Factor κB Ligand-Receptor Activator of Nuclear Factor KB Signaling Pathway in Myeloma Bone Disease

Cardiac Complications of Multiple Myeloma Treatments

Multiple myeloma: signaling pathways and targeted therapy

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

New diagnostic strategy for multiple myeloma: A review

Molecular Pathogenesis of Multiple Myeloma

Myeloma bone and extra-medullary disease: Role of PET/CT and other whole-body imaging techniques

Myeloma bone disease: Progress in pathogenesis.

Pathogenesis of bone disease in multiple myeloma: from bench to bedside

Myeloma and Bone Disease